Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Mullins, Stefanie R.; Vasilakos, John P.; Deschler, Katharina; Grigsby, Iwen; Gillis, Pete; John, Julius; Elder, Matthew J.; Swales, John; Timosenko, Elina; Cooper, Zachary; Dovedi, Simon J.; Leishman, Andrew J.; Luheshi, Nadia; Elvecrog, James; Tilahun, Ashenafi; Goodwin, Richard; Herbst, Ronald; Tomai, Mark A.; Wilkinson, Robert W.

doi:10.1186/s40425-019-0724-8

Article metrics
Last updated: Thu, 25 Apr 2024 9:49:31 Z

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Access & Citations

14k

Article Accesses
0

Web of Science
114

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

Online attention

13 tweeters

112 Mendeley

This article is in the 81^st percentile (ranked 64,574^th) of the 352,645 tracked articles of a similar age in all journals and the 65^th percentile (ranked 27^th) of the 79 tracked articles of a similar age in Journal for ImmunoTherapy of Cancer

View more on Altmetric

Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.